Literature DB >> 6230182

Complement-mediated solubilization of immune complexes. Solubilization inhibition and complement factor levels in SLE patients.

G Baatrup, I Petersen, E Kappelgaard, H H Jepsen, S E Svehag.   

Abstract

Thirty-two of 36 serum samples from 19 SLE patients showed reduced capacity to mediate complement-dependent solubilization of immune complexes (IC). SLE patients with nephritis exerted the lowest complement-mediated solubilization capacity (CMSC) whereas sera from patients with inactive disease gave the highest CMSC values, with three out of four samples within the normal reference range. Thirty-five of the 36 serum samples showed inhibition of CMSC in a newly developed CMSC inhibition assay. The strongest CMSC inhibition was exerted by sera from newly discovered cases of SLE who received no medical treatment and the lowest inhibition by sera from patients with inactive disease. There was a significant negative correlation between CMSC and CMSC inhibition (r = -0.67, P less than 0.001). Sera with low concentrations of C1q, C3, factor B or high C3d levels showed markedly reduced CMSC values. Pronounced CMSC inhibition was observed only in samples with normal or high factor H values. No significant correlation was found between CMSC or CMSC inhibition and circulating IC levels, but pronounced CMSC inhibition was registered only in strongly IC positive sera.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6230182      PMCID: PMC1535805     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Complement as a regulator of interactions between immune complexes and cell membranes.

Authors:  G W Miller; V Nussenzweig
Journal:  J Immunol       Date:  1974-08       Impact factor: 5.422

2.  Detection and quantitation of immune complexes with a rapid polyethylene glycol precipitation complement consumption method (PEG-CC).

Authors:  I Brandslund; H C Siersted; J C Jensenius; S E Svehag
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

3.  Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.

Authors:  T Sakurai; T Fujita; I Kono; T Kabashima; K Yamane; N Tamura; H Kashiwagi
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

4.  Double-decker rocket immunoelectrophoresis for direct quantitation of complement C3 split products with C3d specificities in plasma.

Authors:  I Brandslund; H C Siersted; S E Svehag; B Teisner
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

5.  Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis.

Authors:  J A Schifferli; S M Morris; A Dash; D K Peters
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

6.  Reduced complement-mediated immune complex solubilizing capacity and the presence of incompletely solubilized immune complexes in SLE sera.

Authors:  G Baatrup; I Petersen; J C Jensenius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

7.  Estimation of immune complexes by a microplate-adapted C1q-Protein A enzyme-linked-immunosorbent-assay (C1q-PA-ELISA).

Authors:  L Bjerrum; G Glikmann; J C Jensenius; S E Svehag
Journal:  J Clin Lab Immunol       Date:  1983-01

8.  Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.

Authors:  M T Aguado; L H Perrin; P A Miescher; P H Lambert
Journal:  Arthritis Rheum       Date:  1981-10

9.  Complement-dependent release of immune complexes from the lymphocyte membrane.

Authors:  G W Miller; P H Saluk; V Nussenzweig
Journal:  J Exp Med       Date:  1973-09-01       Impact factor: 14.307

10.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

  10 in total
  5 in total

1.  Successful therapy of meningococcal sepsis in acute disseminated lupus erythematosus with plasmapheresis, immunosuppression, and antibiotics.

Authors:  G J Dobos; S Meske; E Keller; W Riegel; P Vaith; H H Peter; P Schollmeyer
Journal:  Klin Wochenschr       Date:  1990-10-03

2.  Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

Authors:  J A Schifferli; G Steiger; G Hauptmann; P J Spaeth; A G Sjöholm
Journal:  J Clin Invest       Date:  1985-12       Impact factor: 14.808

3.  Clearance kinetics and organ uptake of complement-solubilized immune complexes in mice.

Authors:  M T Aguado; M Mannik
Journal:  Immunology       Date:  1987-02       Impact factor: 7.397

4.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

Review 5.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.